1. |
From the Editor |
|
Inpharma Weekly,
Volume &NA;,
Issue 999,
1995,
Page 2-2
&NA;,
Preview
|
PDF (1183KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1995
数据来源: ADIS
|
2. |
Oral tolerance therapy - an option on the therapeutic menu for uveitis? |
|
Inpharma Weekly,
Volume &NA;,
Issue 999,
1995,
Page 3-4
Jo Barnes,
Preview
|
PDF (2246KB)
|
|
摘要:
Oral tolerance therapy with retinal antigens is a novel approach to treating patients with uveitis who require conventional immunosuppressive therapy to control their disease. In a pilot study involving 2 patients with uveitis, oral tolerance therapy with bovine retinal soluble antigen allowed the reduction or withdrawal of conventional immunosuppressive therapy, while maintaining good visual function. This approach is now under investigation in a doubleblind, placebo-controlled trial in patients with uveitis who are receiving immunosuppressant therapy. Details of these studies, and data from the preclinical investigations that led to the development of this approach in humans, were presented at the International Symposium on Clinical Immunology [San Francisco, US; July 1995].
ISSN:1173-8324
出版商:ADIS
年代:1995
数据来源: ADIS
|
3. |
News in brief… |
|
Inpharma Weekly,
Volume &NA;,
Issue 999,
1995,
Page 5-5
&NA;,
Preview
|
PDF (1013KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1995
数据来源: ADIS
|
4. |
Is adding ramipril to conventional CHF therapy cost effective? |
|
Inpharma Weekly,
Volume &NA;,
Issue 999,
1995,
Page 6-6
&NA;,
Preview
|
PDF (1041KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1995
数据来源: ADIS
|
5. |
News in brief… |
|
Inpharma Weekly,
Volume &NA;,
Issue 999,
1995,
Page 7-7
&NA;,
Preview
|
PDF (1039KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1995
数据来源: ADIS
|
6. |
DETOXTMboosts antibody response to melanoma vaccine |
|
Inpharma Weekly,
Volume &NA;,
Issue 999,
1995,
Page 8-8
&NA;,
Preview
|
PDF (1179KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1995
数据来源: ADIS
|
7. |
Compassionate use of RP-59500 in endocarditis |
|
Inpharma Weekly,
Volume &NA;,
Issue 999,
1995,
Page 9-9
Rosie Stather,
Preview
|
PDF (1158KB)
|
|
摘要:
RP-59500 [Synercid®; Rhône-Poulenc Rorer; phase III], is an injectable water-soluble streptogramin. It has been made available for the past 2 years under a compassionate-use programme for the treatment of vancomycinresistantEnterococcus faecium(VREF) infection, and for the treatment of infections caused by other Gram-positive pathogens in patients who cannot tolerate or have not responded to treatment with vancomycin. Details of 5 patients who received treatment with RP-59500 for endocarditis were presented at the 3rd International Sympo- sium on Modern Concepts in Endocarditis [Boston, US; July 1995].
ISSN:1173-8324
出版商:ADIS
年代:1995
数据来源: ADIS
|
8. |
News in brief… |
|
Inpharma Weekly,
Volume &NA;,
Issue 999,
1995,
Page 10-10
&NA;,
Preview
|
PDF (1047KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1995
数据来源: ADIS
|
9. |
News in brief… |
|
Inpharma Weekly,
Volume &NA;,
Issue 999,
1995,
Page 11-11
&NA;,
Preview
|
PDF (1091KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1995
数据来源: ADIS
|
10. |
Hormone replacement therapy and lipid levels |
|
Inpharma Weekly,
Volume &NA;,
Issue 999,
1995,
Page 12-12
&NA;,
Preview
|
PDF (1026KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1995
数据来源: ADIS
|